Poor survival of females with bladder cancer is limited to those aged 70 years or over: a population-wide linkage study, New South Wales, Australia
Abstract:
Although men are diagnosed with bladder cancer (BC) with a rate three times higher than women, women experience poorer survival. The cause of this gender difference is not clear. The aim of this study was to investigate the discrepancy in survival from BC by gender and explore potential explanations for the difference using a population-wide linkage study. Using the New South Wales (NSW) Central Cancer Registry, all invasive BC cases diagnosed between 2001 and 2009 were identified. Records were linked to the NSW Admitted Patient Data Collection (APDC), to retrieve treatment details, and to the Registry of Births Deaths and Marriages and Australian Bureau of Statistics to obtain death details. A total of 5377 new cases of BC were identified. No differences were identified in the proportions of patients presenting at different stages between genders. However, disease-specific survival (DSS) was worse for females compared to males with localized and regional disease (P < 0.05). This difference was only apparent in individuals aged ≥70 years and no difference was identified in those younger. Multivariable Cox-regression analysis of the cohort of individuals aged ≥70 years revealed that stage, age, comorbidity, and sex remained independent variables (P < 0.05) predicting DSS. In a population wide analysis, females aged 70 years or more suffer worse DSS compared to males. The differences are not accounted for by stage at presentation or comorbidity and are independent of age. BC in postmenopausal females may be biologically more aggressive.
Keywords:
Age; bladder cancer; gender; sex; survival
Autoři:
Manish I. Patel 1; Albert Bang 2; David Gillett 3; Rajkumar Cheluvappa 1; David P. Smith 4
Působiště autorů:
Westmead Hospital, Discipline of Surgery, University of Sydney, Sydney, NSW, Australia
1; Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia
2; Department of Surgery, Macquarie University, Sydney, NSW, Australia
3; Griffith Health Institute, Griffith University, Nathan, Queensland, Australia
4
Vyšlo v časopise:
Cancer Medicine 2015; 4(8)
Kategorie:
Original Research
prolekare.web.journal.doi_sk:
https://doi.org/10.1002/cam4.452
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Souhrn
Abstract:
Although men are diagnosed with bladder cancer (BC) with a rate three times higher than women, women experience poorer survival. The cause of this gender difference is not clear. The aim of this study was to investigate the discrepancy in survival from BC by gender and explore potential explanations for the difference using a population-wide linkage study. Using the New South Wales (NSW) Central Cancer Registry, all invasive BC cases diagnosed between 2001 and 2009 were identified. Records were linked to the NSW Admitted Patient Data Collection (APDC), to retrieve treatment details, and to the Registry of Births Deaths and Marriages and Australian Bureau of Statistics to obtain death details. A total of 5377 new cases of BC were identified. No differences were identified in the proportions of patients presenting at different stages between genders. However, disease-specific survival (DSS) was worse for females compared to males with localized and regional disease (P < 0.05). This difference was only apparent in individuals aged ≥70 years and no difference was identified in those younger. Multivariable Cox-regression analysis of the cohort of individuals aged ≥70 years revealed that stage, age, comorbidity, and sex remained independent variables (P < 0.05) predicting DSS. In a population wide analysis, females aged 70 years or more suffer worse DSS compared to males. The differences are not accounted for by stage at presentation or comorbidity and are independent of age. BC in postmenopausal females may be biologically more aggressive.
Keywords:
Age; bladder cancer; gender; sex; survival
Zdroje
1. Currow, D., and W. Thomson. 2014. Cancer in NSW: Incidence Report 2009. Cancer Institute NSW, Sydney.
2. Cheluvappa, R., D. P. Smith, S. Cerimagic, and M. I. Patel. 2014. A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. Int. Urol. Nephrol. 46:1351–1360.
3. Duncombe, J., E. Stavrou, W. Chen, D. Baker, E. Tracey, and J. Bishop. 2009. Bladder Cancer in New South Wales. Cancer Institute NSW, Sydney.
4. Mungan, N. A., K. K. Aben, M. P. Schoenberg, O. Visser, J. W. Coebergh, J. A. Witjes, et al. 2000. Gender differences in stage-adjusted bladder cancer survival. Urology 55:876–880.
5. Mungan, N. A., L. A. Kiemeney, J. A. van Dijck, H. G. van der Poel, and J. A. Witjes. 2000. Gender differences in stage distribution of bladder cancer. Urology 55:368–371.
6. Puente, D., N. Malats, L. Cecchini, A. Tardón, R. García-Closas, C. Serra, et al. 2003. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur. Urol. 43:53–62.
7. Svatek, R. S., S. F. Shariat, C. P. Dinney, G. Novara, Y. Fradet, P. J. Bastian, et al. 2009. Evidence gender related outcomes after radical cystectomy: results of a large multicentre study. J. Urol. 181:629. Absract #1744.
8. Jeldres, C., H. Isbarn, U. Capitanio, S. Baillargeon-Gagne, N. Bhojani, S. F. Shariat et al. 2009. Gender is an important predictor of cancer-specific survival in patient with transitional cell carcinoma after radical cystectomy. J. Urol. 181:635. Abstract #1761.
9. Tracey, E., H. Watt, D. Currow, J. Young, and B. Armstrong. 2013. Investigation of poorer bladder cancer survival in women in NSW, Australia: a data linkage study. BJU Int. 113:437–48.
10. Tracey, E., D. Roder, C. Luke, and J. Bishop. 2009. Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men? BJU Int. 104:498–504.
11. Mitra, A. P., E. C. Skinner, A. K. Schuckman, D. I. Quinn, T. B. Dorff, and S. Daneshmand. 2014. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urol. Oncol. 32:52.e51–52.e59.
12. Scosyrev, E., D. Golijanin, G. Wu, and E. Messing. 2012. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int. 109:57–62.
13. Taub, D. A., B. K. Hollenbeck, K. L. Cooper, R. L. Dunn, D. C. Miller, J. M. Taylor, et al. 2006. Racial disparities in resource utilization for cystectomy. Urology 67:288–293.
14. Shariat, S. F., J. P. Sfakianos, M. J. Droller, P. I. Karakiewicz, S. Meryn, and B. H. Bochner. 2010. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 105:300–308.
15. Statistics. ABo. 1998. Australian Bureau of Statistics 1996. Census of population and housing. Socioeconomic indexes for areas. Australian Bureau of Statistics, Canberra.
16. Care DoHaA, Adelaide. atUo. 1999. Measuring remoteness: Accessibility/Remoteness Index of Australia (ARIA). Occasional papers. Commonwealth of Australia, Canberra.
17. Esteban, D., S. Whelan, A. Laudico, and D. M. Parkin. 1995. Coding. Pp. 4.32 in D. Esteban, S. Whelan, A. Laudico, D. M. Parkin, eds. Manual for cancer registry personnel: IARC technical report no 10. International Agency for Research on Cancer, Lyon.
18. Kaushik, D., I. Frank, M. S. Eisenberg, J. C. Cheville, R. Tarrell, P. Thapa, et al. 2013. Gender-specific survival following radical cystectomy for pT4 bladder cancer. World J. Urol. 32:1433–9.
19. Horstmann, M., R. Witthuhn, M. Falk, and A. Stenzl. 2008. Gender-specific differences in bladder cancer: a retrospective analysis. Gend. Med. 5:385–394.
20. Scelo, G., and P. Brennan. 2007. The epidemiology of bladder and kidney cancer. Nat. Clin. Pract. Urol.4:205–217.
21. Kluth, L. A., M. Rieken, E. Xylinas, M. Kent, M. Rink, M. Rouprêt, et al. 2014. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur. Urol. 66:913–9.
22. Wood, D. P. 2006. Urothelial Tumours of the Bladder. Pp. 2309–34 in A.J. Wein, L. R. Kavoussi, A. C. Novic, A. W. Partin, C. A. Peters eds. Campbell-Walsh Urology. Saunders-Elsevier, Philadelphia.
23. Heiner, J. G., and M. K. Terris. 2008. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol. Oncol. 26:137–140.
24. Herr, H. W. 2007. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology 70:65–68.
25. Prout, G. R., Jr., M. N. Wesley, R. Yancik, L. A. Ries, R. J. Havlik, and B. K. Edwards. 2005. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer104:1638–1647.
26. McGrath, M., D. S. Michaud, and I. De Vivo. 2006. Hormonal and reproductive factors and the risk of bladder cancer in women. Am. J. Epidemiol. 163:236–244.
27. Zhuang, Y. H., M. Blauer, T. Tammela, and P. Tuohimaa. 1997. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 30:556–562.
28. Boorjian, S, S. Ugras, N. P. Mongan, L. J. Gudas, X. You, S. K. Tickoo, et al. 2004. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64:383–388.
29. Miyamoto, H, Z. Yang, Y. T. Chen, H. Ishiguro, H. Uemura, Y. Kubota, et al. 2007. Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer Inst. 99:558–568.
30. Saez, S., and P. M. Martin. 1981. Evidence of estrogen receptors in the trigone area of human urinary bladder. J. Steroid Biochem. 15:317–320.
Štítky
OnkológiaČlánok vyšiel v časopise
Cancer Medicine
2015 Číslo 8
- Nejasný stín na plicích – kazuistika
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- První a jediná schválená imunoterapie vzácného agresivního karcinomu kůže
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Preskripce léčebného konopí: Kterým pacientům pomůžete nejvíc?
Najčítanejšie v tomto čísle
- Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
- The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multiinstitutional phase II study
- Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections
- Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma